Advances in Nanocarriers for Delivering Therapeutic Agents Against Hepatitis B Virus

IF 4 Q2 ENGINEERING, BIOMEDICAL

Advanced Nanobiomed Research Pub Date : 2024-03-25 DOI:10.1002/anbr.202300132

Jia Li, Jianlan Yuan, Hugang Li, Jingyi Guo, Mingjun Li, Tingbin Zhang, Xing-Jie Liang, Haiming Fan, Xiaoli Liu

{"title":"Advances in Nanocarriers for Delivering Therapeutic Agents Against Hepatitis B Virus","authors":"Jia Li, Jianlan Yuan, Hugang Li, Jingyi Guo, Mingjun Li, Tingbin Zhang, Xing-Jie Liang, Haiming Fan, Xiaoli Liu","doi":"10.1002/anbr.202300132","DOIUrl":null,"url":null,"abstract":"<p>Hepatitis B virus (HBV) infection is a crucial public health issue and a major cause of liver disease, such as cirrhosis and hepatocellular carcinoma. At present, orally administered small molecule drugs, such as nucleoside / nucleotide analogues, are recommended as the first-line treatment for HBV. However, the therapeutic efficacy of these drugs is hindered by off-target toxicity caused by the whole-body permeation distribution of these oral drugs. As an emerging drug delivery technology, systemically administered nanocarriers can enhance the aqueous solubility and stability of encapsulated drugs, prolong circulation times, and deliver them efficiently to the liver, showing great promise for increasing the safety and efficacy of small molecule drugs. Furthermore, nanocarriers also accelerate the clinical translation of new therapies, such as nucleic acids and vaccines. This review article highlights the progress of nanoparticle delivery systems in anti-HBV therapeutics and discusses the opportunities and challenges for the future development of anti-HBV nanotherapeutics.</p>","PeriodicalId":29975,"journal":{"name":"Advanced Nanobiomed Research","volume":"4 6","pages":""},"PeriodicalIF":4.0000,"publicationDate":"2024-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/anbr.202300132","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced Nanobiomed Research","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/anbr.202300132","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}

引用次数: 0

Abstract

Hepatitis B virus (HBV) infection is a crucial public health issue and a major cause of liver disease, such as cirrhosis and hepatocellular carcinoma. At present, orally administered small molecule drugs, such as nucleoside / nucleotide analogues, are recommended as the first-line treatment for HBV. However, the therapeutic efficacy of these drugs is hindered by off-target toxicity caused by the whole-body permeation distribution of these oral drugs. As an emerging drug delivery technology, systemically administered nanocarriers can enhance the aqueous solubility and stability of encapsulated drugs, prolong circulation times, and deliver them efficiently to the liver, showing great promise for increasing the safety and efficacy of small molecule drugs. Furthermore, nanocarriers also accelerate the clinical translation of new therapies, such as nucleic acids and vaccines. This review article highlights the progress of nanoparticle delivery systems in anti-HBV therapeutics and discusses the opportunities and challenges for the future development of anti-HBV nanotherapeutics.

Abstract Image

查看原文本刊更多论文

用于输送乙型肝炎病毒治疗药物的纳米载体的研究进展

乙型肝炎病毒（HBV）感染是一个重要的公共卫生问题，也是肝硬化和肝细胞癌等肝病的主要病因。目前，口服小分子药物（如核苷/核苷酸类似物）被推荐为治疗 HBV 的一线药物。然而，这些口服药物的全身渗透分布造成的脱靶毒性阻碍了这些药物的疗效。作为一种新兴的给药技术，全身给药纳米载体可以提高封装药物的水溶性和稳定性，延长循环时间，并将药物有效地输送到肝脏，在提高小分子药物的安全性和有效性方面大有可为。此外，纳米载体还能加速核酸和疫苗等新疗法的临床转化。这篇综述文章重点介绍了纳米颗粒给药系统在抗 HBV 疗法中的应用进展，并探讨了抗 HBV 纳米疗法未来发展的机遇与挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Advanced Nanobiomed Research nanomedicine, bioengineering and biomaterials-

CiteScore

5.00

自引率

5.90%

发文量

审稿时长

21 weeks

期刊介绍： Advanced NanoBiomed Research will provide an Open Access home for cutting-edge nanomedicine, bioengineering and biomaterials research aimed at improving human health. The journal will capture a broad spectrum of research from increasingly multi- and interdisciplinary fields of the traditional areas of biomedicine, bioengineering and health-related materials science as well as precision and personalized medicine, drug delivery, and artificial intelligence-driven health science. The scope of Advanced NanoBiomed Research will cover the following key subject areas: ▪ Nanomedicine and nanotechnology, with applications in drug and gene delivery, diagnostics, theranostics, photothermal and photodynamic therapy and multimodal imaging. ▪ Biomaterials, including hydrogels, 2D materials, biopolymers, composites, biodegradable materials, biohybrids and biomimetics (such as artificial cells, exosomes and extracellular vesicles), as well as all organic and inorganic materials for biomedical applications. ▪ Biointerfaces, such as anti-microbial surfaces and coatings, as well as interfaces for cellular engineering, immunoengineering and 3D cell culture. ▪ Biofabrication including (bio)inks and technologies, towards generation of functional tissues and organs. ▪ Tissue engineering and regenerative medicine, including scaffolds and scaffold-free approaches, for bone, ligament, muscle, skin, neural, cardiac tissue engineering and tissue vascularization. ▪ Devices for healthcare applications, disease modelling and treatment, such as diagnostics, lab-on-a-chip, organs-on-a-chip, bioMEMS, bioelectronics, wearables, actuators, soft robotics, and intelligent drug delivery systems. with a strong focus on applications of these fields, from bench-to-bedside, for treatment of all diseases and disorders, such as infectious, autoimmune, cardiovascular and metabolic diseases, neurological disorders and cancer; including pharmacology and toxicology studies.